Get the Stockscreener App
2.38
0.83%
-0.02
Pre-market:
2.48
0.10
+4.20%
Aptevo Therapeutics Inc stock is traded at $2.38, with a volume of 9,520.
It is down -0.83% in the last 24 hours and down -34.62% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$2.40
Open:
$2.42
24h Volume:
9,520
Relative Volume:
0.05
Market Cap:
$3.47M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0245
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-11.19%
1M Performance:
-34.62%
6M Performance:
-81.88%
1Y Performance:
-98.70%
1-Day Range:
$2.354
$2.49
1-Week Range:
$2.354
$2.67
52-Week Range:
$2.354
$207.33
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
2.38 | 3.47M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Increase in Short Interest - Defense World
APVO stock plunges to 52-week low of $2.48 amid steep annual decline - Investing.com Australia
APVO stock plunges to 52-week low of $2.48 amid steep annual decline By Investing.com - Investing.com South Africa
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Aptevo to Participate in March Conferences - ACCESS Newswire
Can These Two Major Biotech Conferences Unlock Aptevo's Next Growth Phase? - StockTitan
APVO stock plunges to 52-week low, touches $3 mark - Investing.com
APVO stock plunges to 52-week low, touches $3 mark By Investing.com - Investing.com South Africa
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World
Aptevo Therapeutics (APVO) Projected to Post Quarterly Earnings on Tuesday - Defense World
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition - ACCESS Newswire
Roth Capital Brokers Decrease Earnings Estimates for APVO - Defense World
FY2029 Earnings Estimate for APVO Issued By Roth Capital - Defense World
Aptevo Therapeutics files $100M mixed securities shelf - MSN
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission RateCEO Interview Alert - StockTitan
Aptevo Therapeutics Inc. (APVO) reports earnings - Quartz
Aptevo Therapeutics Inc. SEC 10-K Report - TradingView
Aptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last year - TipRanks
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - StockTitan
APVO stock plunges to 52-week low at $3.62 amid steep annual decline - MSN
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - ACCESS Newswire
APVO stock plunges to 52-week low at $3.62 amid steep annual decline By Investing.com - Investing.com South Africa
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding - ACCESS Newswire
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale - ACCESS Newswire
Aptevo Therapeutics Showcases Promising Oncology Drug Pipeline - TipRanks
TG Therapeutics (NASDAQ:TGTX) vs. Aptevo Therapeutics (NASDAQ:APVO) Head-To-Head Review - Defense World
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decline in Short Interest - Defense World
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - ACCESS Newswire
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting - ACCESS Newswire
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - ACCESS Newswire
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion - ACCESS Newswire
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire
Aptevo Therapeutics Announces Closing of $2.75 Million Offering - ACCESS Newswire
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire
Aptevo's Senior Director to Present ADAPTIR Platform at Major Biotech Conference PepTalk 2025 - StockTitan
Trend Tracker for (APVO) - Stock Traders Daily
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year? - Yahoo Finance
Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish - MSN
APVO stock touches 52-week low at $5.1 amid sharp annual decline - Investing.com Australia
Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial - Marketscreener.com
Aptevo reports full remission in AML trial - Investing.com India
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):